![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Sustained Immune Control in HBeAg-Positive Chronic Hepatitis B Patients Who Switched From Long-Term Entecavir Therapy to Peginterferon Alfa-2a (40KD): 1-Year Follow-Up of the OSST Study
|
|
|
Reported by Jules Levin
AASLD 2013 Nov 1-5 Wash DC
M. Han,1 J. Jiang,2 J. Hou,3 D. Tan,4 Y. Sun,5 M. Zhao,6 Q. Ning;1 on behalf of the OSST study group
1Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; 2The First Hospital, Fujian Medical University, Fuzhou, China; 3Nanfang Hospital, Nanfang Medical University, Guangzhou, China;4Xiangya Hospital, Central South University, Changsha, China; 5Tangdu Hospital, The Fourth Military Medical University, Xi'an, China; 6Shanghai Roche Pharmaceuticals Co., Ltd, Shanghai, China
![AASLD1.gif](../images/112213/112213-1/AASLD1.gif)
![AASLD2.gif](../images/112213/112213-1/AASLD2.gif)
![AASLD3.gif](../images/112213/112213-1/AASLD3.gif)
![AASLD4.gif](../images/112213/112213-1/AASLD4.gif)
![AASLD5.gif](../images/112213/112213-1/AASLD5.gif)
![AASLD6.gif](../images/112213/112213-1/AASLD6.gif)
![AASLD7.gif](../images/112213/112213-1/AASLD7.gif)
![AASLD8.gif](../images/112213/112213-1/AASLD8.gif)
![AASLD9.gif](../images/112213/112213-1/AASLD9.gif)
![AASLD10.gif](../images/112213/112213-1/AASLD10.gif)
![AASLD11.gif](../images/112213/112213-1/AASLD11.gif)
![AASLD12.gif](../images/112213/112213-1/AASLD12.gif)
![AASLD13.gif](../images/112213/112213-1/AASLD13.gif)
![AASLD14.gif](../images/112213/112213-1/AASLD14.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|